EU extends safety review of chronic Hepatitis C treatments

EU extends safety review of chronic Hepatitis C treatments

The European health regulator said it extended a safety review of chronic hepatitis C treatments after new data showed patients taking the drugs were at risk of their liver cancer returning.

“The study suggested that these patients were at risk of their cancer coming back earlier than patients with hepatitis C who were not treated with direct-acting antivirals,” the European Medicines Agency (EMA) said.

The review covers some of the top-selling products in the multi-billion dollar hepatitis C market. These drugs cure well over 90 percent of patients with the liver disease and cut down the treatment duration.

The EMA cited Bristol-Myers Squibb Co’s Daklinza, AbbVie Inc’s Exviera and Viekirax, Gilead Sciences Inc’s Harvoni and Sovaldi and Johnson & Johnson’s Olysio in its statement.

The safety review extension follows the release of new data this month from a study.

The EMA started its review last month after the hepatitis B virus re-activated in patients who were infected both by hepatitis B and C viruses, and were being treated with the heptatitis C drugs.

Tags:

health European union EU hepatitis C

Want to send us a story? Submit on Wananchi Reporting on the Citizen Digital App or Send an email to wananchi@royalmedia.co.ke or Send an SMS to 25170 or WhatsApp on 0743570000

Leave a Comment

Comments

No comments yet.

latest stories